Openbookopenbook
Equity
Heron Therapeutics Inc.(0J4V)
USD --+0.00%
Reward50Moderate
Risk72High
📊75%Data
Thin -13% profit margin
0J4V
+0.0 · +0.00%
USD · LSE
Heron Therapeutics Inc. |
Earnings Deterioration
Market Cap:—
ℹ️
Reward Rating
50
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
72
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0J4V to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Heron Therapeutics Inc.?

, a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care.

0J4V · Verdict

Moderate reward · high risk

0J4V has limited near-term tailwinds — cash flow and profitability weigh on the model output.

Based on 88% data coverage

0J4V · Verdict

What’s working & what to watch

Watchouts 4

  • Cash flow12/100

    -18% free-cash-flow margin

  • Profitability32/100

    -13% net margin · -2409% ROE

  • Volatility35/100

    Below average

  • Balance sheet39/100

    Current ratio 2.48

Model-based scoring. For information only — not financial advice.

What is Heron Therapeutics Inc.?

, a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. The company is listed on the LSE in UK.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (50)

The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market CapN/A
P/E RatioN/A
Dividend YieldN/A
52 Week High2.61
52 Week Low0.75
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares Outstanding78M
No. of Employees128
IndustryN/A
ExchangeLSE
Beta1.424
CurrencyUSD
Websitewww.herontx.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.